Clinical Scorecard: Chronic Inflammation in Hidradenitis Suppurativa: Insights into Pathogenesis and Treatment Strategies

At a Glance

Key Highlights

• HS is characterized by nodules, abscesses, and sinus tracts in apocrine gland-bearing skin.
• Meta-inflammation is a key mechanism linking HS with metabolic syndrome.
• HS is associated with significant comorbidities including inflammatory bowel disease and cardiovascular disease.
• The disease process involves both local skin pathology and systemic inflammatory responses.
• Immunometabolic therapies may complement existing treatments for HS.
• HS has systemic implications, impacting overall health and quality of life.

Guideline-Based Recommendations

Diagnosis

• Recognize HS as a chronic relapsing autoinflammatory skin disorder.
• Consider the systemic implications and comorbidities associated with HS.

Management

• Implement multidisciplinary therapeutic approaches targeting both skin inflammation and metabolic dysfunction.
• Incorporate lifestyle interventions and immunometabolic therapies.

Monitoring & Follow-up

• Monitor for comorbid conditions such as metabolic syndrome and inflammatory bowel disease.

Risks

• Patients may experience significant impacts on quality of life, including insomnia, anxiety, and depression.

Patient & Prescribing Data

Focus on lifestyle interventions, weight management, and immuno-metabolic therapies to improve outcomes.

Clinical Best Practices

• Address both cutaneous inflammation and underlying metabolic alterations in treatment plans.
• Utilize a holistic management strategy for HS, emphasizing multidisciplinary collaboration.

Related Resources & Content

• Hidradenitis Suppurativa Overview